EDX Medical Group PLC - Cambridge, England-based company that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Signs in-licensing agreement with Oxford University patent portfolio manager Oxford University Innovation Ltd. Agreement to allow EDX access to intellectual property funded by Cancer Research UK and developed at Oxford and Birmingham Universities.
Says agreement will allow EDX to develop a safety and dose management test for patients receiving 5-fluorouracil capecitabine and other chemotherapy drugs with potential serious side effects used against colorectal cancer, breast cancer and cancers of the upper gastrointestinal tract. Says test will examine patient genes to determine susceptibility to adverse effects prior to dosing. Will be available exclusively from EDX and developed under its partnership with Massachusetts-based life science and clinical research company Thermo Fisher Scientific Ltd.
Chief Executive Officer Mike Hudson says: ‘We are continuing to broaden our range of cancer testing solutions wherever we see a need to provide doctors with timely information on individual patient’s biology which can translate to improved treatment and outcomes. By including several new gene targets, the new product is expected to set a new standard in this important area of pharmacogenomic drug safety, enabling a more complete and accurate prediction of dose-related side effects and clinical risks for patients of various ethnicities receiving 5-fluorouracil and capecitabine.’
EDX current share price: 9.75 pence
12-month change: More than trebled from 2.88 pence
Thermo Fisher current share price: $601.88
12-month change: up 10%
Copyright 2024 Alliance News Ltd. All Rights Reserved.
